SLDB - Solid Biosciences Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.96
+0.46 (+5.41%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.50
Open8.73
Bid8.87 x 800
Ask8.99 x 1000
Day's Range8.50 - 9.12
52 Week Range5.97 - 54.84
Volume1,060,655
Avg. Volume766,809
Market Cap317.475M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.33
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.83
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    Lifshitz & Miller LLP Announces Investigation of Bristow Group Inc., Helius Medical Technologies, Inc., Nordstrom Inc., PriceSmart, Inc., Ryanair Holdings plc, Solid Biosciences Inc., and Vanda Pharmaceuticals Inc.

    NEW YORK , Feb. 20, 2019 /PRNewswire/ -- Bristow Group Inc. (BRS) Lifshitz & Miller  announces investigation into possible securities laws violations in connection with the Company disclosing that it "did ...

  • Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
    Zacks8 days ago

    Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review

    FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.

  • Why Solid Biosciences Stock Nosedived 67.82% Yesterday
    Market Realist15 days ago

    Why Solid Biosciences Stock Nosedived 67.82% Yesterday

    Why Solid Biosciences Stock Nosedived 67.82% YesterdayStock price movements On February 7, Solid Biosciences (SLDB) closed at $7.19, 67.82% lower than its previous closing price, 5.27% higher than its 52-week low of $6.83, and 86.89% below its

  • What Solid Biosciences' First Failure Means for Sarepta Therapeutics
    Motley Fool16 days ago

    What Solid Biosciences' First Failure Means for Sarepta Therapeutics

    Here's why a competitor's pain was Sarepta's gain recently.

  • Why This Biotech Stock Cratered 68% On Its Gene Therapy Study
    Investor's Business Daily16 days ago

    Why This Biotech Stock Cratered 68% On Its Gene Therapy Study

    Solid Biosciences crashed Thursday after its experimental gene therapy disappointed in a study of Duchenne muscular dystrophy patients. Sarepta Therapeutics, a rival, saw shares pop.

  • Barrons.com16 days ago

    A Setback for Solid Is a Win for Sarepta in Race to Treat Muscular Dystrophy

    Sarepta Therapeutics solidified its position as the leader in developing a gene therapy for Duchenne muscular dystrophy following disappointing data from a clinical trial released Thursday.

  • Business Wire16 days ago

    SHAREHOLDER ALERT: Investigation of Solid Biosciences Inc. Announced by Holzer & Holzer, LLC

    Holzer & Holzer, LLC is investigating whether certain statements made by Solid Biosciences, Inc. complied with federal securities laws.

  • Here's Why Solid Biosciences Plunged Today
    Motley Fool16 days ago

    Here's Why Solid Biosciences Plunged Today

    The company announced disappointing early results for a muscular dystrophy gene therapy.

  • Solid Biosciences shares drop 70% on disappointing Duchenne data
    American City Business Journals16 days ago

    Solid Biosciences shares drop 70% on disappointing Duchenne data

    Cambridge biotech Solid Biosciences' stock dropped more than 70 percent Thursday after its Duchenne muscular dystrophy drug failed to come close to the effectiveness of its competitor in early tests.

  • Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains
    Bloomberg16 days ago

    Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains

    The drugmaker fell 73 percent at the market open in New York while shares of Sarepta gained more than 4 percent. JPMorgan analyst Anupam Rama, who has had an underweight rating on Solid Bio for almost a year, said the study update shows the “worst-case scenario” is playing out for the small-cap company. Solid Bio Chief Executive Officer Ilan Ganot said in a phone interview that “the data do not affect our timeline or the competitive nature of our program.” The company said last month that animal models suggested a patient benefit “in the range of 10% or higher” compared to the minimal results seen this morning.

  • MarketWatch16 days ago

    Solid Biosciences stock falls 73% after preliminary Phase 1/2 trial shows efficacy issues with drug

    Shares of Solid Biosciences fell 73% in premarket trade Tuesday after the company said preliminary findings from a Phase 1/2 clinical trial of lead candidate SGT-001 found that patients with Duchenne muscular dystrophy (DMD) who were treated with the drug showed low levels of microdystrophin protein expression. DMD is caused by mutations in the dystrophin gene -- people with the mutation can't make dystrophin protein, which is usually present in skeletal and cardiac muscles and helps protect them from injury. SGT-001 is a drug that delivers to the body a synthetic form of the dystrophin gene that codes for a replacement protein called microdystrophin. The six patients in Solid Biosciences' early-phase trial showed low levels of microdystrophin even after being treated, something the company believes can be fixed with higher doses of the drug. "We believe that SGT-001 will be a meaningful treatment for patients with DMD and are confident we have the right approach in place to evaluate its potential at higher doses. We have already begun working to expedite the planned dose escalation strategy outlined in our clinical trial protocol," said Ilan Ganot, co-founder, CEO and president of Solid Biosciences. Shares of the company have declined 17% in the year to date, while the S&P 500 has gained 9%.

  • GlobeNewswire17 days ago

    Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy

    Solid Biosciences (SLDB) announced today preliminary findings from IGNITE DMD, the Company’s Phase I/II dose-ascending clinical trial evaluating the safety and efficacy of SGT-001 microdystrophin gene transfer for the treatment of Duchenne muscular dystrophy (DMD). Initial three-month biopsy data showed low levels of microdystrophin protein expression. The Company is currently engaging with the appropriate parties to dose escalate as planned and as soon as possible.

  • GlobeNewswire2 months ago

    Solid Biosciences to Present at the J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 02, 2019 -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot, Co-Founder, Chief Executive Officer and President of Solid Biosciences.

  • Solid Biosciences’ Stock Price Rose 10.5% on November 13
    Market Realist3 months ago

    Solid Biosciences’ Stock Price Rose 10.5% on November 13

    On November 13, Solid Biosciences’ (SLDB) stock price closed at $31.94, which represents ~10.48% growth from the close of $28.91 on November 12. On November 13, Solid Biosciences’ stock price increased after it presented its third-quarter financial results.

  • ACCESSWIRE4 months ago

    How This Underfollowed $6 Biotech Could Be Worth $10

    The emerging cell therapy company Orgenesis Inc (ORGS) continues to prove they've got the right stuff, growing their revenue 50% in fiscal Q3 over the previous quarter and 143% compared to the previous year. The company just signed another high-profile Cell Therapy company, Iovance Biotherapeutics (IOVA), as a client, joining Crispr Therapeutics (CRSP) and Adaptimmune (ADAP) among others. As they continue to sign clients, grow revenue, and add global manufacturing capacity, valuation metrics suggest this NASDAQ listing could be substantially undervalued.

  • Solid Biosciences and Its Focus on Duchenne Muscular Dystrophy
    Market Realist5 months ago

    Solid Biosciences and Its Focus on Duchenne Muscular Dystrophy

    Solid Biosciences (SLDB) is focused on developing products that treat Duchenne muscular dystrophy (or DMD), a genetic muscle-wasting disease caused by mutations in the dystrophin gene. Solid Biosciences’ SGT-001 is being developed to restore functional dystrophin protein expression in patients’ muscles. The drug has received rare pediatric disease designation in the United States and orphan drug designation in the United States and the European Union.

  • What Solid Biosciences’ Valuation Trend Indicates
    Market Realist5 months ago

    What Solid Biosciences’ Valuation Trend Indicates

    Solid Biosciences (SLDB) incurred a net loss of $17.98 million in the second quarter of 2018, which compares to a net loss of $11.31 million in the second quarter of 2017, translating to a net loss per share of $0.52 in the second quarter of 2018. Its net loss per share was $0.66 in the second quarter of 2017. The decrease in net loss per share was due to an increase in the company’s outstanding shares, which increased from 17.04 million in the second quarter of 2017 to 34.45 million in the second quarter of 2018.

  • BioMarin Pharmaceutical and Its Promising Research Pipeline
    Market Realist5 months ago

    BioMarin Pharmaceutical and Its Promising Research Pipeline

    Stocks focused on gene therapy have garnered strong investor interest in 2018. While some of them have been climbing steadily, others have received strong price corrections on pipeline news. In this series, we’ll analyze four companies: BioMarin Pharmaceutical (BMRN), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), and uniQure (QURE).

  • Benzinga6 months ago

    Credit Suisse Joins Consensus To Prescribe Sarepta

    The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT ). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold. The Rating Credit Suisse analysts ...